Correlation Between Eliem Therapeutics and Biohaven Pharmaceutical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Biohaven Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Biohaven Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Biohaven Pharmaceutical Holding, you can compare the effects of market volatilities on Eliem Therapeutics and Biohaven Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Biohaven Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Biohaven Pharmaceutical.

Diversification Opportunities for Eliem Therapeutics and Biohaven Pharmaceutical

-0.62
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Eliem and Biohaven is -0.62. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Biohaven Pharmaceutical Holdin in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biohaven Pharmaceutical and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Biohaven Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biohaven Pharmaceutical has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Biohaven Pharmaceutical go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Biohaven Pharmaceutical

Given the investment horizon of 90 days Eliem Therapeutics is expected to generate 2.02 times more return on investment than Biohaven Pharmaceutical. However, Eliem Therapeutics is 2.02 times more volatile than Biohaven Pharmaceutical Holding. It trades about 0.04 of its potential returns per unit of risk. Biohaven Pharmaceutical Holding is currently generating about 0.05 per unit of risk. If you would invest  251.00  in Eliem Therapeutics on September 2, 2024 and sell it today you would earn a total of  53.00  from holding Eliem Therapeutics or generate 21.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy99.19%
ValuesDaily Returns

Eliem Therapeutics  vs.  Biohaven Pharmaceutical Holdin

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Biohaven Pharmaceutical 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Biohaven Pharmaceutical Holding are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Biohaven Pharmaceutical displayed solid returns over the last few months and may actually be approaching a breakup point.

Eliem Therapeutics and Biohaven Pharmaceutical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and Biohaven Pharmaceutical

The main advantage of trading using opposite Eliem Therapeutics and Biohaven Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Biohaven Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will offset losses from the drop in Biohaven Pharmaceutical's long position.
The idea behind Eliem Therapeutics and Biohaven Pharmaceutical Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Money Managers
Screen money managers from public funds and ETFs managed around the world